Related Experiment Video
Updated: Feb 7, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Downregulation of hepatic lipase is associated with decreased CD133 expression and clone formation in HepG2 cells
Xuehua Liu1, Junhua Zuo2, Yuan Fang1
1Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Abstract:
The drug resistance of cancer remains a major obstacle to successful chemotherapy. New strategies for improving chemotherapeutic efficacy are urgently required. Recent studies have indicated that LIPC plays a role in promoting the liver metastasis of colorectal cancer. In the present study, we aimed to investigate the effects of LIPC on theproliferation and clone formation of colorectal cancer-derived cells, and chemoresistance in hepatoblastoma-derived HepG2 cells. The activity and expression of LIPC were determined in the cell lines by RT-qPCR and western blot analysis. HepG2 cells in which LIPC was knocked down by LIPC short hairpin RNA (shRNA) and control cells [shRNA control (shCON)] were established and analyzed for cell proliferation and colony formation rates. FACS analysis was used to explore the association between LIPC and the tumor-derived cell biomarker, CD133, and the percentages of CD133-positive cells were assessed by FACS. Additionally, shLIPC- and shCON-transfected cells were treated with various concentrations of doxorubicin and 5-floxuridine (5-FU), and cell viability was determined by MTT assay. mRNA levels in the shLIPC- and shCON-transfected cells were compared by cDNA microarray and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The results revealed that the HepG2 cells exhibited a relatively higher LIPC activity and expression levels compared to the other colon cancer cell lines. The downregulation of LIPC in the HepG2 cells was associated with the decreased expression of CD133, decreased cell proliferation and colony formation, as well as increased resistance to chemotherapy. KEGG analysis of the cDNA microarray data revealed increased levels in the cell adhesion molecule (CAM) pathway, including CLDN10 and CLDN1, indicating that CAMs may play a role in LIPC-mediated tumor progression. The present findings indicate a potential role of LIPC as a promising therapeutic target in cancer.
Insights
Lipase C (LIPC) downregulation in HepG2 cells reduced cancer cell proliferation and chemoresistance. LIPC inhibition also decreased CD133 expression and affected cell adhesion molecule pathways, suggesting LIPC as a potential cancer therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Cancer drug resistance impedes chemotherapy efficacy, necessitating novel therapeutic strategies.
- Lipase C (LIPC) has been implicated in promoting colorectal cancer liver metastasis.
- Understanding LIPC's role in cancer progression and chemoresistance is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the effects of LIPC on colorectal cancer cell proliferation, clone formation, and chemoresistance.
- To analyze the relationship between LIPC expression, CD133 biomarker, and chemotherapy response in HepG2 cells.
- To explore molecular pathways influenced by LIPC, including cell adhesion molecules (CAMs).
Main Methods:
- Lipase C (LIPC) activity and expression were quantified using RT-qPCR and Western blot in HepG2 cells.
- LIPC was downregulated using short hairpin RNA (shRNA) in HepG2 cells; proliferation, colony formation, and chemoresistance (doxorubicin, 5-FU) were assessed.
- Flow cytometry (FACS) analyzed CD133 expression, while cDNA microarray and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified affected molecular pathways.
Main Results:
- HepG2 cells exhibited higher LIPC activity and expression compared to other colon cancer cell lines.
- LIPC downregulation decreased CD133 expression, reduced cell proliferation and colony formation, and increased chemoresistance.
- KEGG analysis revealed altered cell adhesion molecule (CAM) pathways, including CLDN10 and CLDN1, suggesting LIPC's role in tumor progression.
Conclusions:
- Downregulation of LIPC in HepG2 cells correlates with reduced proliferation, colony formation, and increased chemoresistance.
- LIPC inhibition impacts CD133 expression and influences CAM pathways, highlighting its multifaceted role in cancer.
- Lipase C (LIPC) represents a potential therapeutic target for improving chemotherapeutic efficacy in colorectal cancer.
Related Concept Videos
Reproductive Cloning
Somatic Cell Nuclear Transfer
In SCNT, an egg cell is taken from an animal and its nucleus is removed, creating an enucleated egg. Then a somatic...
Decreasing Function
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Decreased Body Temperature
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Cell Specific Gene Expression

